Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine 19Cyclophosphamide 19fludarabine phosphate 16Azacitidine 14Tacrolimus 13Melphalan 13venetoclax 10Cytarabine 10Busulfan 10Whole-Body Irradiation 9Thiotepa 9Mycophenolic Acid 9Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Decitabine 7decitabine and cedazuridine drug combination 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Sirolimus 5CPX-351 5AP 1903 reagent 5thymoglobulin 4Vorinostat 4Mesna 4Injections 4Daunorubicin 4Biopsy 4Ipilimumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic Syndromes × Liposomes × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡